NCT06085521

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Lynk Pharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.

Detailed description

The study was to include a 12-week double-blind treatment period. Participants who met eligibility criteria were to be randomized in a 1:1:1 ratio to one of the three treatment groups. Group 1:LNK01001 dose A (Day 1 to Week 12) Group 2:LNK01001 dose B (Day 1 to Week 12) Group 3: Matching placebo (Day 1 to Week 12)

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	LNK01001 Dose A	Capsules taken orally
DRUG	LNK01001 Dose B	Capsules taken orally
DRUG	placebo	Capsules taken orally

Timeline

• Start date: 2022-01-26
• Primary completion: 2023-06-14
• Completion: 2023-06-14
• First posted: 2023-10-17
• Last updated: 2023-10-27

Locations

1 site across 1 country: China